Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P40616
UPID:
ARL1_HUMAN
Alternative names:
-
Alternative UPACC:
P40616; B4DWW1; P80417; Q53XB1
Background:
ADP-ribosylation factor-like protein 1 is a pivotal GTP-binding protein, orchestrating a myriad of cellular processes by recruiting effectors such as golgins, arfaptins, and Arf-GEFs to the trans-Golgi network. It modulates functions at the Golgi complex, influencing cell polarity, innate immunity, and protein secretion. Notably, arfaptins contribute to maintaining insulin secretion from pancreatic beta cells, highlighting the protein's broad impact on cellular physiology.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor-like protein 1 could open doors to potential therapeutic strategies.